PD-1 and CTLA-4 dual inhibitor peptides

    公开(公告)号:AU2018273958A1

    公开(公告)日:2020-01-02

    申请号:AU2018273958

    申请日:2018-05-25

    Applicant: LEIDOS INC

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

    PD-1 peptide inhibitors
    4.
    发明专利

    公开(公告)号:AU2017325866B2

    公开(公告)日:2021-09-09

    申请号:AU2017325866

    申请日:2017-09-15

    Applicant: LEIDOS INC

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PDL1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

    PD-1 PEPTIDE INHIBITORS
    6.
    发明专利

    公开(公告)号:CA3036251A1

    公开(公告)日:2018-03-22

    申请号:CA3036251

    申请日:2017-09-15

    Applicant: LEIDOS INC

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PDL1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

    LAG 3 binding peptides
    7.
    发明专利

    公开(公告)号:AU2020279371A1

    公开(公告)日:2021-12-23

    申请号:AU2020279371

    申请日:2020-05-21

    Applicant: LEIDOS INC

    Abstract: This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

Patent Agency Ranking